[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5261607A1 - Nuevo uso - Google Patents

Nuevo uso

Info

Publication number
CO5261607A1
CO5261607A1 CO00087729A CO00087729A CO5261607A1 CO 5261607 A1 CO5261607 A1 CO 5261607A1 CO 00087729 A CO00087729 A CO 00087729A CO 00087729 A CO00087729 A CO 00087729A CO 5261607 A1 CO5261607 A1 CO 5261607A1
Authority
CO
Colombia
Prior art keywords
alkyl
zero
hydrogen
jpeg
heteroaryl
Prior art date
Application number
CO00087729A
Other languages
English (en)
Inventor
Michael Balestra
George Byron Mullen
Phillips Eifion
Richard Schmiesing
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5261607A1 publication Critical patent/CO5261607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula general I<EMI FILE="00087729_1" ID="1" IMF=JPEG >en donde:A representa<EMI FILE="00087729_2" ID="2" IMF=JPEG >D representa oxígeno, o azufre;R1 representa hidrógeno o metil;R2 representa hidrógeno, o alquil C1-C4;R3 representa<EMI FILE="00087729_3" ID="3" IMF=JPEG >R4, R5, y R6 son independientemente hidrógeno, halógeno, alquil C1-C4 alquenil C2-C4, alquinil C2-C4, -CO2R7, -CN, -CF3, ó Ar, con la condición de que por lo menos uno entre R4 y R5 representa Ar; Ar representa un anillo aromático ó heteroaromático de 5 ó 6-miembros que contiene de cero a tres átomos de nitrógeno, cero ó un átomo de oxígeno, y cero ó un átomo de azufre, ó un sistema anular aromático ó heteroaromático fusionado de 8, 9 ó 10 miembros que contiene de cero a cuatro átomos de nitrógeno, cero ó un átomo de oxígeno, y cero ó un átomo de azufre, sistemas anulares los cuales pueden ir opcionalmente sustituidos con uno ó más sustituyentes seleccionados entre los siguientes: hidrógeno, halógeno, alquil C1-C4, alquenil C2-C4, alquinil C2-C4, aril, heteroaril, -CO2R7, -CN, -NO2, -NR8R9-, -CF3, -OR10; R8, R9, y R10 son independientemente hidrógeno alquil C1-C4, aril, heteroaril, -C(O)R11, -C(O)NHR12, -C(O)R13, -SO2R14 ó R8 y R9 tomados en conjunto pueden formar (CH2)jQ(CH2)k en donde Q es O, S, NR15, ó un enlace: j toma valores entre 2 y 4; k toma valores entre 0 y 2; R7, R10, R11, R12, R13, R14, y R15, son independientemente alquil C1-C4, aril ó heteroaril; ó un enantiómero de éste, y las sales farmacéuticamente aceptables de éste, con la condición adicional de que Ar no represente 2-, 3-, 4-piridil, fenil no sustituido ó fenil sustituido con uno ó más sustituyentes seleccionados entre alquil C1-C4, alcoxi C1-C4, halógeno, fenoxi, hidroxi, OCOR11, NH2, NHCOR11, ...
CO00087729A 1999-11-18 2000-11-17 Nuevo uso CO5261607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use

Publications (1)

Publication Number Publication Date
CO5261607A1 true CO5261607A1 (es) 2003-03-31

Family

ID=20417766

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00087729A CO5261607A1 (es) 1999-11-18 2000-11-17 Nuevo uso

Country Status (31)

Country Link
US (1) US6683090B1 (es)
EP (1) EP1233964B1 (es)
JP (1) JP2003514818A (es)
KR (1) KR20020058014A (es)
CN (1) CN1217943C (es)
AR (1) AR031680A1 (es)
AT (1) ATE298337T1 (es)
AU (1) AU784400B2 (es)
BG (1) BG106680A (es)
BR (1) BR0015624A (es)
CA (1) CA2389604A1 (es)
CO (1) CO5261607A1 (es)
CZ (1) CZ20021692A3 (es)
DE (1) DE60020994T2 (es)
DK (1) DK1233964T3 (es)
EE (1) EE200200251A (es)
ES (1) ES2242653T3 (es)
HK (1) HK1047743A1 (es)
HU (1) HUP0204245A3 (es)
IL (1) IL149374A0 (es)
IS (1) IS6385A (es)
MX (1) MXPA02004911A (es)
NO (1) NO20022289L (es)
NZ (1) NZ518571A (es)
PL (1) PL355867A1 (es)
PT (1) PT1233964E (es)
SE (1) SE9904176D0 (es)
SK (1) SK6772002A3 (es)
UA (1) UA74172C2 (es)
WO (1) WO2001036417A1 (es)
ZA (1) ZA200203316B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AU2001282874A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
EP1311505A2 (en) * 2000-08-21 2003-05-21 PHARMACIA &amp; UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
CN1229375C (zh) * 2001-07-06 2005-11-30 神经研究公司 烟碱型乙酰胆碱受体抑制剂化合物、其制备和应用
EP1419161A1 (en) 2001-08-24 2004-05-19 PHARMACIA &amp; UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease
EA007429B1 (ru) 2001-10-02 2006-10-27 Фармация Энд Апджон Компани Азабициклические замещённые конденсированные гетероарильные соединения
WO2003032897A2 (en) * 2001-10-16 2003-04-24 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
BR0213760A (pt) * 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0214031A (pt) 2001-11-08 2004-10-19 Upjohn Co Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
BR0214929A (pt) 2001-12-14 2006-05-30 Targacept Inc métodos e composições para o tratamento de distúrbios do sistema nervoso central
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003210730A1 (en) 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
JP2005523287A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療用アザビシクロ化合物
AU2003227522A1 (en) 2002-05-30 2003-12-19 Neurosearch A/S 3-substituted quinuclidines and their use
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
WO2004019943A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
PL377777A1 (pl) * 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
US7402592B2 (en) 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
BRPI0614874A2 (pt) 2005-08-22 2011-04-19 Targacept Inc diazatricicloalcanos substituìdos com heteroarila, métodos para sua preparação e uso dos mesmos
WO2007037258A1 (ja) * 2005-09-28 2007-04-05 Kumamoto University 注意欠陥・多動性障害の治療薬
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US9233106B2 (en) * 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR101565469B1 (ko) 2007-10-01 2015-11-03 코멘티스, 인코포레이티드 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
NO3029039T3 (es) 2010-05-17 2018-01-20
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
WO2012177856A2 (en) * 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
EP3010900B1 (en) 2013-06-21 2018-01-03 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255467B (it) * 1992-07-29 1995-11-02 Dompe Farmaceutici Spa Ammidi acriliche farmacologicamente attive
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5981525A (en) * 1995-01-10 1999-11-09 Smithkline Beecham Corporation Indole derivatives useful in the treatment of osteoporosis

Also Published As

Publication number Publication date
MXPA02004911A (es) 2002-09-18
HK1047743A1 (en) 2003-03-07
CA2389604A1 (en) 2001-05-25
CN1423651A (zh) 2003-06-11
NO20022289D0 (no) 2002-05-14
CZ20021692A3 (cs) 2003-01-15
JP2003514818A (ja) 2003-04-22
DK1233964T3 (da) 2005-09-19
PL355867A1 (en) 2004-05-31
WO2001036417A1 (en) 2001-05-25
ZA200203316B (en) 2004-02-25
DE60020994T2 (de) 2006-04-27
HUP0204245A2 (hu) 2003-03-28
EP1233964A1 (en) 2002-08-28
BR0015624A (pt) 2002-07-30
IS6385A (is) 2002-05-15
DE60020994D1 (de) 2005-07-28
ATE298337T1 (de) 2005-07-15
KR20020058014A (ko) 2002-07-12
AR031680A1 (es) 2003-10-01
AU784400B2 (en) 2006-03-23
UA74172C2 (uk) 2005-11-15
SK6772002A3 (en) 2002-09-10
NZ518571A (en) 2004-05-28
AU1907301A (en) 2001-05-30
BG106680A (bg) 2003-01-31
CN1217943C (zh) 2005-09-07
SE9904176D0 (sv) 1999-11-18
HUP0204245A3 (en) 2004-12-28
NO20022289L (no) 2002-06-24
ES2242653T3 (es) 2005-11-16
US6683090B1 (en) 2004-01-27
EP1233964B1 (en) 2005-06-22
IL149374A0 (en) 2002-11-10
EE200200251A (et) 2003-06-16
PT1233964E (pt) 2005-09-30

Similar Documents

Publication Publication Date Title
CO5261607A1 (es) Nuevo uso
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
ES2188280T3 (es) Acetales heteroaril-ciclicos.
CO5280079A1 (es) Nuevos compuestos
DK7280A (da) Fremgangsmaade til fremstilling af (piperidinylalkyl) quinazolin-derivater
EA200100428A1 (ru) Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
ATE29255T1 (de) Succinimid-derivate und deren herstellung.
PT99919A (pt) Processo para a preparacao de derivados de xantina
CO5251458A1 (es) Nuevos compuestos
HUP9901331A2 (hu) Ciklooxigenáz inhibitorok amidinszármazékokkal alkotott sói, eljárás előállításukra, ezeket tartalmazó gyógyászati készítmények
IL135924A0 (en) Urea derivatives and their use as integrin inhibitors
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
PT1202954E (pt) Novas aminobenzofenonas
ATE199543T1 (de) Bibphenylamid-derivate als 5-ht1d-antagonisten
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
DK0925295T3 (da) Derivater af N-benzensulfonyl-L-prolin som antagonister af receptoren B2 for bradykinin
DK447284A (da) Aminoderivater af 2-(n-(2,2,5,5-tetramethyl-3-pyrrolin-3-carbonyl)),deres fremstilling og anvendelse
MY130750A (en) Pyrimidine derivatives useful as selective cox-2 inhibitors
HUP0001009A2 (hu) Herbicid hatású 3-karbamoil/3-tiokarbamoil-szubsztituált 2-benzoil-ciklohexán-1,3-dionok, intermedierjeik, előállításuk és alkalmazásuk
CO5231148A1 (es) Compuesros herbicidas derivados de la piridina-2,6- sustituida, procedimiento para prepararlos, las composiciones herbicidas que los contienen, el procedimiento de aplicacion de dichos compuestos y el uso de los mismos como herbicidas
CO5160340A1 (es) Nuevos derivados de morfolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DK406587A (da) 1,4-dihydropyridinderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse

Legal Events

Date Code Title Description
FC Application refused